论文部分内容阅读
目的了角攀枝花市城镇居民医保慢性病患者门诊诊疗费用支付现况,探讨慢性病患者门诊诊疗费用变化趋势。方法依据2011-2014年市医疗保险管理局提供慢性病患者门诊费用数据,分析慢性病门诊总费用支付情况、每种疾病门诊费用支付情况及其变化趋势。采用SPSS 17.0统计软件对2011-2014年攀枝花市城镇居民医保慢性病患者门诊医疗费用原始数据进行对比分析。结果 2011-2014年慢性病门诊总费用34 998.8万元,年增长率为18.8%,排名前5位的疾病分别是糖尿病(14 840.6万元,42.4%),高血压(9 159.9万元,26.2%),冠心病(4 436.0万元,12.7%%),慢性阻塞性肺气肿(1 547.3万元,4.4%)及恶性肿瘤(1 084.9万元,3.1%),总费用共计31 068.7万元,占总支出的88.8%,年增长率为19.3%。慢性病门诊就诊853 827人次,年增长率为7.9%,平均就诊费用(410.84±318.53)元,年增长率为10.1%。结论慢性病门诊费用主要用于糖尿病、高血压及冠心病患者,应加强这3种疾病重点人群的预防及治疗。
The purpose of this paper is to find out the status quo of outpatient service payment for urban residents who are covered by medical insurance in Panzhihua City, and to explore the changing trend of outpatient service costs in chronic patients. Methods Based on the data of outpatient service costs of chronic disease patients provided by the City Medical Insurance Administration from 2011 to 2014, the total cost of chronic disease outpatient services, the outpatient payment of each disease and its changing trend were analyzed. The SPSS 17.0 statistical software was used to compare the out-patient medical costs of urban residents with medical insurance for chronic diseases in 2011-2014 in Panzhihua City. Results The total cost of chronic diseases clinics in 2011-2014 was 349.98 million yuan, with an annual growth rate of 18.8%. The top five diseases were diabetes (146.46 million yuan, 42.4%), hypertension (9.1599 million yuan, 26.2% ), Coronary heart disease (43.36 million yuan, 12.7%), chronic obstructive pulmonary emphysema (5.447 million yuan, 4.4%) and malignant tumors (10.149 million yuan, 3.1%), with a total cost of 31.0687 million yuan , Accounting for 88.8% of the total expenditure, an annual growth rate of 19.3%. 853 827 visits were made to chronic disease clinics, with an annual growth rate of 7.9% and an average consultation fee of (410.84 ± 318.53) yuan, an annual increase rate of 10.1%. Conclusion The cost of chronic disease outpatient service is mainly used in patients with diabetes, hypertension and coronary heart disease. Prevention and treatment should be strengthened in key populations of these three diseases.